Public Employees Retirement System of Ohio grew its position in Bristol-Myers Squibb Company (NYSE:BMY) by 0.7% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 1,160,692 shares of the biopharmaceutical company’s stock after buying an additional 8,339 shares during the period. Public Employees Retirement System of Ohio owned 0.07% of Bristol-Myers Squibb worth $64,674,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Blue Chip Partners Inc. increased its stake in shares of Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares during the period. Jackson Grant Investment Advisers Inc. increased its stake in shares of Bristol-Myers Squibb by 0.4% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 15 shares during the period. Shayne & CO. LLC increased its stake in shares of Bristol-Myers Squibb by 0.6% in the 2nd quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 24 shares during the period. Chilton Investment Co. LLC increased its stake in shares of Bristol-Myers Squibb by 0.5% in the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock valued at $294,000 after buying an additional 26 shares during the period. Finally, Greenleaf Trust grew its stake in shares of Bristol-Myers Squibb by 0.4% during the second quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock worth $535,000 after purchasing an additional 39 shares during the period. 69.82% of the stock is owned by institutional investors.

A number of equities research analysts recently commented on the company. BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Monday. Citigroup set a $72.00 price objective on Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Tuesday, December 5th. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. SunTrust Banks raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Finally, Credit Suisse Group reaffirmed a “hold” rating and set a $61.00 price objective (up from $58.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $64.93.

In other news, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares in the company, valued at $37,031,717.01. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company (NYSE:BMY) opened at $63.28 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The firm has a market capitalization of $103,144.84, a PE ratio of 21.29, a price-to-earnings-growth ratio of 2.39 and a beta of 1.18. Bristol-Myers Squibb Company has a twelve month low of $46.01 and a twelve month high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The business had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.77 earnings per share. equities analysts predict that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, January 4th. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.53%. Bristol-Myers Squibb’s payout ratio is currently 61.42%.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/public-employees-retirement-system-of-ohio-grows-stake-in-bristol-myers-squibb-company-bmy/1761302.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.